# GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

> **NCT05861336** · PHASE2 · WITHDRAWN · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Losartan
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT05861336
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-14
- **Primary completion:** 2024-12-23
- **Final completion:** 2024-12-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients enrolled
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861336, "GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05861336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*